[78] Despite the frequent expression of EGFR, the rarity of activating mutations predictive of response to EGFR tyrosine kinase inhibitors (TKIs) makes unlikely that this class of drugs will be clinically effective for ACC. The gene discussed is EGFR; the disease is adrenal cortex carcinoma.